Hematology News

NEW ORLEANS —One-time treatment with the gene therapy betibeglogene autotemcel continued to demonstrate long-term efficacy among patients with transfusion-dependent beta-thalassemia, study results showed.

An external classical hematology mentorship pilot program appeared to have a positive influence on trainees and their career paths, according to study results presented at ASH Annual Meeting and Exposition.

An aspirin de-implementation intervention appeared associated with reduced bleeding risk patients hospitalized with atrial fibrillation and/or venous thromboembolism and taking warfarin, according to data published in JAMA Network Open.

Endogenous C1 esterase inhibitor is an important negative regulator of coagulation, according to study results presented at ASH Annual Meeting and Exposition.

NEW ORLEANS — Efgartigimod demonstrated clinically significant improvement in platelet counts compared with placebo among adults with primary immune thrombocytopenia, results of the phase 3 ADVANCE IV trial showed.

NEW ORLEANS — Patients with cancer and COVID-19 exhibited a 3% risk for thromboembolism within 30 days of their first positive test, according to study results presented at ASH Annual Meeting and Exposition.

Gene therapy could represent an equitable therapeutic strategy for sickle cell disease in the United States, according to study results presented at ASH Annual Meeting and Exposition.

Irving Weissman, MD, will receive the Wallace H. Coulter Award for Lifetime Achievement in Hematology at this year’s ASH Annual Meeting & Exposition.

Members of racial and ethnic minority groups had lower odds of receiving advanced therapies for pulmonary embolism and higher odds of in-hospital mortality compared with white individuals, according to study results.

James Gavin, MD, PhD, and David Wilkes, MD, will receive the ASH award for Leadership in Promoting Diversity at this year’s ASH Annual Meeting & Exposition.